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ABSTRACT
Objective: Assessing the quality of life of adult patients with hematological cancer in 
the 100 days after transplantation of hematopoietic stem cells and verifying whether the 
variable graft-versus-host disease (GvHD) is predictive of worse results. Method: An 
observational correlational and quantitative study with 36 adult participants diagnosed 
with hematologic cancer who underwent hematopoietic stem cell transplantation from 
September 2013 to June 2015. Result: The mean age was 37 years, 52.78% were female, 
and 61.11% were diagnosed with leukemia. Quality of life scores showed a significant 
impact between pre-transplantation and pre-hospital discharge, and also within the 
100 days post-transplantation. The statistical analysis between the scores for the groups 
with and without GvHD showed a significant difference between the presence of the 
complication and worse results. Conclusion: Quality of life is altered as a result of 
hematopoietic stem cells transplantation, especially in patients who have graft-versus-
host disease.
DESCRIPTORS
Quality of Life; Hematopoietic Stem Cell Transplantation; Graft vs Host Disease; 
Oncology Nursing.
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INTRODUCTION
The number of hematopoietic stem cell transplantations 
(HSCT) has progressively increased in recent years and has 
benefited patients with hematologic cancer(1). In Brazil 1,239 
transplants were performed in 2004, and this number rose 
to 2,013 in 2014, with 371 of these being performed in 
the southern region of the country(2). However, this therapy 
introduces complications, such as graft-versus-host disease 
(GvHD), which impacts on quality of life (QoL), in addi-
tion to interfering in biological, psychological, cognitive 
and social aspects of the patient and their family. Thus, it 
is important that health professionals assess the QoL of 
patients in order to help them understand and overcome 
what occurs during and after the transplant(3-4).
Occurrences during HSCT vary with the stages; these 
are didactically divided in order to consider the risks to 
which patients are exposed, in addition to the symptoms. 
Conditioning is the period immediately preceding the 
HSCT, characterized by infusing high doses of cytotoxic 
agents with the goal to eradicate the disease, inducing 
immune suppression in order to reduce graft rejection, which 
is mediated by host cells(5).
Immediate and late post-transplantation is the period in 
which nurses have to deal with the greatest physical, emo-
tional and social changes arising from the therapeutic itiner-
ary, changes in individual roles and social isolation. A post-
transplantation period lasting around 100 days represents a 
milestone in the treatment trajectory, since it corresponds 
to the end of a critical period and a stage when most of the 
potentially lethal complications occur.
Among the complications that concern the patient 
after HSCT, consequences of the toxic effects of high-
dose chemotherapy may be highlighted such as muco-
sitis, diarrhea and vomiting, as well as those relating to 
the pre-existing comorbidities. Successful treatment of 
these complications is influenced by characteristics of each 
patient and the number of previous transfusions and sus-
ceptibility to infections caused by the post-conditioning 
pancytopenia period(6).
The nursing staff has an important role in inserting 
practices for prevention, early detection and managing 
the complications that follow HSCT(7), and among these 
is GvHD.
GvHD occurs when donor lymphocytes recognize the 
host as strange and initiate an immune process of attacking 
recipient cells(8). It is related to epithelial tissue damage 
frequently caused by the conditioning regime, which leads 
to secreting inflammatory cytokines and culminating in the 
infiltration of effector donor cells attacking recipient cells(9) .
This complication leads to high rates of morbidity, lim-
iting survival and causing poorer QoL, which can occur 
from the earliest days preceding medullar attachment until 
months after HSCT(10).
Diagnoses differentiate the disease in acute and chronic 
broad categories by a score of clinical manifestations in 
affected organs, and the subcategories describe disease sever-
ity and treatment indications(11).
Acute GvHD is characterized by inflammatory com-
ponents(5), where skin, liver and digestive tract are the main 
targets. Skin manifestations appear in the form of erythema 
maculopapular rash, and liver impairment is evaluated by 
bilirubin and liver enzyme serum levels, while the severity of 
gastrointestinal damage is evaluated by the presence of vom-
iting, diarrhea volume, abdominal pain and gastrointestinal 
bleeding(6). On the other hand, chronic GvHD resembles 
valvular diseases that present autoimmune and fibrotic char-
acteristics. In general it can be classified according to its 
affective extension, being limited when it is only located in 
one organ or tissue, or as extensive when spanning multiple 
organs(5). The simultaneous occurrence of acute GvHD and 
chronic GvHD results in syndrome overlap, which is associ-
ated with high mortality rates(6).
It should be noted that the concrete need for nursing 
care in the course of this complication is unpredictable, since 
individual demands should be considered(12), and to this end, 
knowledge about the impact of GvHD on QoL after HSCT 
should be punctuated in order to provide care that minimizes 
changes to patient’s QoL. Thus, the guiding question arises: 
Is GvHD related to worsening results of QoL?
Consequently, the present research aimed to assess the 
QoL of adult patients with hematological cancer in 100 days 
of HSCT and check if the GvHD variable is predictive of 
worse results.
METHOD
An observational, correlational and quantitative study 
performed at the Bone Marrow Transplantation Service of a 
public hospital in the southern region of Brazil, being a refer-
ence service for this treatment modality in Latin America.
Inclusion criteria were: being over 18 years old, diag-
nosed with hematologic cancer and being submitted to 
HSCT. Patients who did not have the physical conditions 
to complete the questionnaires were excluded, however there 
was no occurrence of such exclusion. Discontinuity criteria 
included death of the patient or the participant not respond-
ing to the questionnaires within the proposed period.
The study sample consisted of 36 participants, corre-
sponding to 100% of patients with hematologic cancer who 
underwent HSCT at the study site; among these, 32 partici-
pants were in the pre-hospital discharge period and 25 in the 
100-day post-HSCT. Losses occurred due to deaths (n = 10) 
and loss of follow-up contact after hospital discharge (n = 1).
Data collection was performed between September 2013 
and June 2015 with 36 participants who met the inclusion 
criteria, and one was discontinued. The sociodemographic 
and clinical profile was characterized by a specific question-
naire, and two questionnaires were used for QoL evalua-
tion: the generic questionnaire Quality of life Questionnaire 
Core 30 (QLQ-C30), version 3.0 in Portuguese, developed 
by the European Organization Research Treatment of Cancer 
(EORTC), and Functional Assessment Cancer Therapy – 
Bone Marrow Transplantation (FACT-BMT), version 4.0 
in Portuguese, specific for assessment of QoL in HSCT 
and developed by the Functional Assessment of Chronic Illness 
Therapy (FACIT), with both validated for Brazil.
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The questionnaires were applied in three significant 
stages of HSCT. In Pre-HSCT, before the conditioning 
regimen, to establish the baseline level of QoL; at pre-hos-
pital discharge, a period considered a milestone that ends 
hospitalization and initiates outpatient follow-up; and at 100 
days post-HSCT, which represents the end of the critical 
transplant period.
Sociodemographic and clinical data were analyzed 
with descriptive statistics expressed in simple and absolute 
frequency. In relation to the data obtained from the QoL 
questionnaires, these were organized into tables, expressed 
as mean, minimum value, maximum value and standard 
deviation, and examined according to EORTC(13) and 
FACIT guidelines(14).
The non-parametric Friedman test complemented by 
the least significant difference test for multiple comparisons 
(p-value) were used for comparing the scores obtained in 
each stage, in which results with p<0.05 are significant. The 
use of non-parametric tests is justified due to the lack of 
normality of the data, an assumption verified by the Shapiro-
Wilk Test. The pre-transplantation stage was compared with 
pre-hospital discharge, and the pre-transplant with 100 
days post-HSCT; also, pre-hospital discharge with 100 days 
post-HSCT.
The global QoL score on the QLQ-C30 (score of 0 to 
100 points) and the general QoL score of the FACT-BMT 
(0 to 148 points) were considered for statistical calculations 
of QoL and presence of GvHD, and then Mann-Whitney 
U test was applied.
Ethical aspEcts
After registering the research in the organizations that 
developed the QoL evaluation tools (EORTC and FACIT), 
the use of the questionnaires was authorized by download 
directly to the researcher in charge. Studies using instruments 
from these organizations are highlighted in the discussion.
This study is part of the thematic project Evaluation of 
Quality of life of Adult Patients with Hematologic Neoplasia 
Submitted to Hematopoietic Stem Cell Transplantation, which 
followed the ethical precepts of Resolution 466/12 and 
was developed after the approval of the Research Ethics 
Committee of the Biological Sciences and Health Sector of 
the Universidade Federal do Paraná, under opinion number 
411.548/2013.
In order to insert the participants in the study, they were 
informed about the research objectives, voluntary participa-
tion, risks and benefits, as well as about data collection peri-
odicity. Participants signed and received one of a two-way 
Free and Informed Consent Form.
RESULTS
The study population (Table 1) consisted of 52.78% 
(n = 19) female, with a mean age of 37 years, and 50% 
(n = 18) in the age group between 18 and 30 years. Regarding 
clinical characteristics, 61.11% (n = 22) had a diagnosis of 
leukemia, 41.67% (n = 15) underwent allogeneic HSCT 
from family donors, and 22.22% (n = 8) developed GvHD 
within the 100 days.
continued...
Table 1 – Characterization of sociodemographic and clinical profile – Curitiba, PR, Brazil, 2013-2015.
Variable Absolute frequency (n = 36) Relative frequency (%)
Age
18-30 years 18 50
31-40 years 4 11.11
41-50 years 5 13.89
Over 50 years 9 25
Mean age 37 years
Gender
Female 19 52.78
Male 17 47.22
Marital status
Married 15 41.67
Divorced 1 2.78
Single 15 41.67
Consensual union 5 13.88
Number of children
None 15 41.67
1 child 5 13.89
2 children 9 25
3 children 4 11.11
More than 3 children 3 8.33
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...continuation
Table 2 – QoL scores obtained in the three stages of the study – Curitiba, PR, Brazil, 2013-2015.
Domains
Basal
(n = 36)
Pre-hospital discharge
(n = 32)
100 days post-HSCT
(n = 25)
Mean Min Max SD Mean Min Max SD Mean Min Max SD
Global QoL
(QLQ-C30) 78.01 33.33 100 18.49 67.71 16.67 100 20.82 73.67 8.33 100 23.78
General QoL
(FACT-BMT) 111.84 48 140 21.93 98.60 62 131 14.52 102 20 148 34.03
Variable Absolute frequency (n = 36) Relative frequency (%)
Education level
Primary education 9 25
Secondary education 17 47.22
Superior education 10 27.78
Occupation
Economically active 21 58.33
Retired 4 11.11
Stay-at-home Mom/Wife 5 13.89
Student 6 16.67
Family income
Up to 1 minimum wage 5 13.89
1 to 3 minimum wages 19 52.78
4 to 10 minimum wages 9 25
10 to 20 minimum wages 3 8.33
Diagnosis
Hodgkin’s Lymphoma 5 13.89
Non-Hodgkin’s lymphoma 1 2.78
Acute lymphoblastic leukemia 9 25
Acute myeloblastic leukemia 10 27.78
Chronic mileloide leukemia 3 8.33
Multiple myeloma 7 19.44
Myelodysplastic syndrome 1 2.78
Time since diagnosis
Less than 1 year 10 27.78
From 1 to 3 years 16 44.44
More than 3 years 10 27.78
Graft type
Autologous 11 30.56
Allogeneic from family donors 15 41.67
Allogeneic from unrelated donors 10 27.77
Cell Source
Bone marrow 15 41.67
Peripheral blood 21 58.33
GvHD within the 100 days post-HSCT
Yes 8 22.22
No 28 77.78
QoL scores evidenced that the lowest mean is related to 
the pre-hospital discharge period, being 67.71 in the QLQ-
C30 and 98.60 in FACT-BMT, as shown in Table 2.
Global QoL of the QLQ-C30 p-value did not show 
any significance between the stages; on the other hand, the 
General QoL of the FACT-BMT p-value shows signifi-
cance between the first and second stages, and between the 
second and third stages (Table 3).
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Statistical analysis between Global QoL scores (QLQ-
C30) of the groups of eight with and without GvHD 
(n = 28) in the three stages of the study showed that patients 
with this complication had statistically significant worse 
QoL in the pre-hospital discharge period (p-value 0.036) 
and for the 100 days (p-value 0.029). Analysis of the General 
QoL (FACT-BMT) showed no significance.
DISCUSSION
The participants of this study were in the age group 
corresponding to the productive and reproductive phases, 
being economically active with an occupation and/or con-
solidated professions/careers, during the phase of constitut-
ing families and with responsibilities inherent to them, of 
which can suffer therapeutic impacts. This data corroborates 
a national study carried out with 30 participants in São 
Paulo(15), as well as an American study conducted with 662 
participants(16). Regarding gender, the study is not compat-
ible with the cancer estimates for the years of 2014 and 
2015, when hematologic malignancies presented higher 
incidence in men(17).
Regarding the diagnosis, the predominance of leuke-
mias corroborates the findings of a North American study in 
which 60% were leukemias(16). It is in line with the estimate 
for cancer in 2015 in Brazil, in which this diagnosis pres-
ents an absolute superior frequency in comparison to other 
hematological malignancies(17).
The most common graft type in the present study was 
allogeneic (69.44%), more specifically, allogeneic from 
family donors, with a percentage of 41.67%. Similar data 
were found in a North American study in which allogeneic 
HSCTs accounted for 53.6%(18). However, it differs from the 
HSCT characteristics performed in 2014 in Brazil, where 
the number of autologous HSCTs (1,275) was higher than 
allogeneic HSCTs (738)(2).
According to the records of the Brazilian Association 
of Organ Transplants(2), the State where the research was 
carried out had a proportionally larger number of allogeneic 
HSCTs in relation to autologous, being the only one (state) 
that performed more than ten per million of the popula-
tion; this evidences the relevance of the cases treated in this 
service, considering that allogeneic transplants have high 
technical complexity in relation to autologous.
The present study demonstrates that the QoL of adult 
patients with hematologic cancer who undergo HSCT 
decreases in the pre-hospital discharge period compared 
to the baseline period, showing a significant improvement 
at 100 days post-HSCT. A similar result was evidenced in 
a study of 159 patients diagnosed with cancer at a HSCT 
unit in the United States(19), unlike what was found in a 
public hospital in the state of São Paulo with 12 patients 
submitted to HSCT. In this, QoL was preserved in the pre-
hospital discharge period except for the physical aspects(20). 
It should be noted that both studies used the FACT-BMT 
instrument, so this decline in the QoL assessment regarding 
physical aspects may be related to the various effects result-
ing from the therapy.
The involvement of physical, social and emotional aspects 
in post-transplantation can lead to a decrease in QoL and 
is related to a number of factors, including: toxic effects of 
chemotherapy such as nausea, vomiting, inappetence, pain, 
skin alterations, impaired body image/perception and sexual 
function, as well as changes arising from the diagnosis, social 
isolation and prolonged hospitalization. All these experi-
enced changes due to illness and HSCT cause symptoms 
such as depression, anxiety, emotional unrest, fear and a sense 
of uncertainty about the future.
Similar results were found in a systematic literature 
review that analyzed 34 articles which applied the QLQ-
C30 questionnaire to approximately 2,800 cancer patients 
submitted to HSCT. In this review, the mean scores found 
in the pre-HSCT were higher than at discharge, and six 
months later the scores were not close, however not higher 
than the initial ones(21).
The data from the present study show that at the end of 
the evaluated period the Basal QoL score recovers. However, 
this data refers to patients diagnosed with cancer, close to 
undergoing a risky treatment with the possibility of cure. 
Thus, despite returning to its initial values at 100 days, QoL 
may be compromised due to the diagnosis of cancer. Thus, 
100 days post-HSCT is not sufficient for the cancer patient 
to present better QoL compared to what it was before receiv-
ing diagnosis of the disease.
It is emphasized that the QoL data of the participants 
are evidenced by the mean and generalizes the behavior of 
adult cancer patients who undergo HSCT. However, patients 
view the health/illness process in different ways, meaning 
that some patients face reality with greater empowerment 
than others(22).
In this sense, the (nursing) team should be prepared to 
provide guidelines regarding doubts and fears throughout 
outpatient follow-up, minimizing the suffering related to 
the treatment. It is also necessary to implement an indi-
vidualized care plan that focuses on the reality to be con-
fronted, preparation for leaving the hospital environment 
and care during the outpatient period, aiming at autonomy 
of the individual and family participation in order to provide 
humanized and quality care(23-24).
Correlation of the presence of GvHD up to 100 days 
with absolute scores on general QoL of QLQ-C30 and 
global QoL of FACT-BMT demonstrated the significant 
relationship between the presence of GvHD with the pre-
hospital discharge and 100 days post-HSCT periods.
A multicenter, prospective, observational cohort 
study conducted by the cGvHD consortium (chronic 
Table 3 – P-value among the three stages of the study – Curitiba, 
PR, Brazil, 2013-2015.
Domains p-value
1st stage 
versus 2nd 
stage
1st stage 
versus 3rd 
stage
2nd stage 
versus 3rd 
stage
Global QoL
(QLQ-C30) 0.1637
General QoL
(FACT-BMT) 0.00007 p < 0.001 p < 0.05
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graft-versus-host disease) with 481 patients presenting this 
complication evaluated the relationship between depression, 
anxiety, QoL, chronic GvHD and functional capacity. They 
concluded that patients with this complication reporting 
depression and anxiety had impaired QoL and functional 
capacity. Additionally, self-reported depression was associ-
ated with lower overall survival(25).
It should be noted that the variable GvHD in this study 
did not identify the affected organ/system and was correlated 
with the general and global QoL scores, which in turn reflect 
all domains of the implemented questionnaires. In this way, 
we can perceive the interference magnitude of this complica-
tion in the QoL of the patients after HSCT. Regardless of 
the characteristic of GvHD, we can state that it is predictive 
of worse QoL.
Another multicenter cohort study also coordinated by 
the cGvHD consortium with 522 patients correlated QoL 
assessed with the FACT-BMT of patients with chronic 
GvHD and age, observing that despite the lower physical 
fitness and functional capacity, patients with advanced age 
demonstrated preserved QoL and similar survival compared 
to younger patients(4).
In this context, it is important to emphasize that knowl-
edge about the disease and its evolution allow for priori-
ties to be established in relation to the care provided(26). 
GvHD and its secondary complications are complex and it 
is important to highlight that the follow-up be performed 
by an outpatient multidisciplinary team in specialized 
HSCT centers(27).
As it is a peculiar complication of specific treatment, 
GvHD must be accompanied by a (nursing) team who 
are attentive to indications of complications and signs of 
improvement which may occur. We emphasize the impor-
tance of accurate and detailed attention given by the nurse, 
having an effective methodology for early observation of 
GvHD indicative signs through a directed physical exami-
nation during patient hospitalization.
In addition to observation and accurate reporting of 
symptoms, the frequency and intensity of symptoms should 
be investigated so that early interventions can be performed, 
as they are essential in the course and evolution of the com-
plication. In order for GvHD to be handled correctly after 
it is detected, nurses need to have scientific and technical 
knowledge as well as human interdisciplinary skills. This 
study provides support for nursing to understand that the 
specific actions in patients with GvHD not only reach the 
symptoms but also impact on the QoL of these patients.
It should be considered that the etiology is in the inflam-
matory process, however consequences go beyond physical 
conditions. These patients have already experienced a diag-
nosis of cancer, and at present being afflicted with GvHD 
regresses their hope of survival, as it is known that morbidity 
and mortality rates increase. Thus, the already impressive 
physical complications are not the only ones that permeate 
the mental state of these individuals.
In being aware that GvHD affects all domains of QoL, 
it is necessary that nurses give attention to the resulting 
effects such as anxiety, social isolation due to the longer time 
of hospitalization and frequent readmissions, self-esteem 
related to body image disorder, and disruptions of normal 
sleep patterns due to the need for nocturnal interventions, 
among others.
Therefore, it is important to emphasize interdisciplinar-
ity as an instrument for the advancing qualitative attention, 
QoL and patient satisfaction. In order to do this, the health 
professionals who evaluate the clinical, epidemiological and 
social aspects are essential in order to achieve an effective 
alternative to the biological model of care(26).
A limitation of this study is related to the sample size, 
since it is restricted to patients with hematologic cancer 
and not to the entire population that undergoes HSCT. 
This also makes it impossible to correlate QoL with allo-
geneic and autologous graft types, as well as sociodemo-
graphic characteristics.
CONCLUSION
The present study found that the QoL of the adult patient 
with hematologic cancer is altered as a result of HSCT, and 
that the presence of GvHD is predictive of worse results; a 
fact that is related to the severity of this complication and 
the potential to affect different organ and systems and have 
an impact on aspects other than physical afflictions.
Nursing inserted in a multiprofessional team has the 
potential to implement actions that improve the QoL of 
these patients, either by management and control of the 
symptomatology related to GvHD, or by stimulating subjec-
tive actions that improve their perception about themselves.
RESUMO
Objetivo: Avaliar a qualidade de vida de pacientes adultos com câncer hematológico nos 100 dias do transplante de células-tronco 
hematopoéticas e verificar se a variável doença do enxerto contra o hospedeiro é preditiva de piores resultados. Método: Estudo 
observacional, correlacional e quantitativo, com 36 participantes adultos, diagnosticados com câncer hematológico que se submeteram 
ao transplante de células-tronco hematopoéticas de setembro de 2013 a junho de 2015. Resultado: A média de idade foi 37 anos, 
52,78% eram do sexo feminino, e 61,11% com diagnóstico de leucemia. Os escores de qualidade de vida demonstraram impacto 
significativo entre o pré-transplante e a pré-alta hospitalar e entre os 100 dias pós-transplante. A análise estatística entre os escores 
dos grupos com e sem doença do enxerto contra o hospedeiro evidenciou significância entre a presença desta complicação e piores 
resultados. Conclusão: A qualidade de vida é alterada em decorrência do transplante de células-tronco hematopoéticas, em especial nos 
pacientes que apresentam doença do enxerto contra o hospedeiro.
DESCRITORES
Qualidade de Vida; Transplante de Células-Tronco Hematopoéticas; Doença Enxerto-Hospedeiro; Enfermagem Oncológica.
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RESUMEN
Objetivo: Evaluar la calidad de vida de paciente adultos con cáncer hematológico los 100 días tras el trasplante de células madre 
hematopoyéticas y verificar si la variable enfermedad del injerto contra huésped es predictiva de peores resultados. Método: Estudio 
observacional, correlacional y cuantitativo, con 36 participantes adultos, diagnosticados con cáncer hematológico que se sometieron 
al trasplante de células madre hematopoyéticas de septiembre de 2013 a junio de 2015. Resultado: El promedio de edad fue 37 años, 
el 52,78% eran del sexo femenino y el 61,11% con diagnóstico de leucemia. Los puntajes de calidad de vida demostraron impacto 
significativo entre el pre trasplante y la pre alta hospitalaria y entre los 100 días post trasplante. El análisis estadístico entre los puntajes 
de los grupos con y sin enfermedad del injerto contra huésped evidenció significación entre la presencia de esa complicación y peores 
resultados. Conclusión: La calidad de vida se modifica como consecuencia del trasplante de células madre hematopoyéticas, en especial 
en los pacientes que presentan enfermedad del injerto contra huésped.
DESCRIPTORES
Calidad de Vida; Trasplante de Células Madre Hematopoyéticas; Enfermedad Injerto contra Huésped; Enfermería Oncológica.
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